MC3 System mRNA-LNP Formulation Standard Protocol

The MC3 System mRNA-LNP formulation standard protocol serves as a critical benchmark in modern lipid nanoparticle delivery technology, designed to ensure efficient mRNA encapsulation, stability, and transfection performance both in vitro and in vivo. The protocol provides detailed specifications for lipid component ratios, preparation conditions, and homogenization processes, enabling reproducible and scalable nanoparticle production while maintaining consistent carrier quality across experimental and manufacturing batches. By following this standardized workflow, researchers can optimize mRNA carrier performance and accelerate the development of vaccines and gene therapy products.

I. Core Information Quick Reference

Lipid Base: DLin-MC3-DMA (MC3)

Applications: In vivo/in vitro mRNA delivery, vaccine development, gene editing

III. Lipid Nanoparticle Preparation Protocol

This section outlines a representative preparation workflow for lipid nanoparticles based on MC3-type ionizable lipid systems. A commonly reported lipid composition in the literature includes DLin-MC3-DMA, DSPC, cholesterol, and PEG-lipid at an approximate molar ratio of 50 : 10 : 35–40 : 1–2. In this example workflow, an RNA-to-total lipid weight ratio of approximately 0.05 (w/w) is used as an initial formulation parameter.

3.1 Preparation of Lipid Mixtures

3.1.1 Preparation of Lipid Stock Solutions

• Dissolve each lipid component separately in absolute ethanol to prepare stock solutions at a concentration of 10 mg/mL.
• Lipid stock solutions can be aliquoted and stored at -20°C for future use. They must be brought to room temperature and thoroughly mixed before use.

Note 1: Ionizable lipids (such as MC3) are usually in a viscous liquid state. Because their viscosity affects pipetting accuracy, it is recommended to use the weighing method for quantification rather than relying on volume measurement.

Note 2: Cholesterol ethanol solutions tend to crystallize at low temperatures. Before use, they must be preheated (>37°C) until completely dissolved to maintain fluidity. Transfers should be performed quickly to prevent the solution from cooling and causing uneven concentrations.

3.1.2 Preparation of Mixed Lipid Working Solution

Mix the lipid stock solutions at the following volumes to prepare a mixed working solution with a total lipid concentration of 10 mg/mL (example based on preparing 1 mL):

• Aspirate the respective lipid stock solutions according to the table above and add them to a clean glass container.
• Vortex thoroughly to obtain a clear, homogeneous lipid ethanol solution. This mixture contains 10 mg of total lipids.
• It is recommended to prepare the mixed lipid working solution fresh before use. If storage is necessary, keep it sealed at -20°C and use within 24 hours.

Note 3: The lipid composition and component ratios can be adjusted based on specific application requirements. Changing the lipid formulation will affect LNP size distribution, polydispersity, encapsulation efficiency, and in vitro/in vivo activity, requiring corresponding adjustments to the mRNA dosage.

3.2 RNA Solution Preparation

• Prepare 100 mM sodium acetate buffer, accurately adjusting the pH to 5.0 with glacial acetic acid or sodium hydroxide.
• Dilute the RNA (using siRNA as an example here, but applicable to mRNA) to the target concentration using the above buffer. Based on an RNA to total lipid weight ratio of 0.05, 0.5 mg of RNA is required for 10 mg of total lipid.
• To satisfy the 3:1 aqueous to organic volume ratio, the volume of the RNA solution must be 3 times that of the lipid mixture. If 1 mL of the lipid mixture is used, 3 mL of RNA solution should be prepared, resulting in a theoretical concentration of 166.7 μg/mL (0.5 mg / 3 mL).

Note 4: The weight ratio of RNA to lipids is a critical parameter affecting encapsulation efficiency. Researchers can optimize this ratio according to their specific system. When altering the RNA amount, the concentration of the lipid mixture or RNA solution must be adjusted accordingly to maintain the preset volume ratio.

3.3 Mixing Process

Common methods for achieving rapid mixing of the ethanol and aqueous phases include the pipette mixing method, vortex mixing method, and microfluidic mixing method. All three can be used for LNP preparation, but they differ in size uniformity, encapsulation efficiency, and batch-to-batch reproducibility.

3.3.1 Pipette Mixing Method

• Place 3 mL of RNA solution (aqueous phase) in a suitable container.
• Aspirate 1 mL of the lipid mixture solution (organic phase) using a pipette.
• Rapidly inject the organic phase into the aqueous phase while immediately pipetting up and down for 20-30 seconds. This must be swift and continuous to ensure both phases mix thoroughly in a short time.
• Incubate the resulting mixture at room temperature for 10-15 minutes to allow the LNPs to fully assemble and mature.
• Proceed with downstream purification as per Section 3.4.

Scope: Rapid exploratory experiments, preliminary condition screening.

Limitations: High manual operation variability, limited batch reproducibility, and potentially broader LNP size distribution.

3.3.2 Vortex Mixing Method

• Place 3 mL of RNA solution (aqueous phase) in a suitable container and set the container on a vortex mixer.
• Turn on the vortex and adjust to a medium speed (approx. 1000-1500 rpm) to form a stable vortex at the liquid surface.
• While continuously vortexing, rapidly inject 1 mL of the lipid mixture solution (organic phase) into the center of the vortex using a pipette or syringe pump.
• Maintain vortexing for 20-30 seconds to ensure thorough contact between the two phases.
• Incubate the resulting mixture at room temperature for 10-15 minutes.
• Proceed with downstream purification as per Section 3.4.

Scope: Medium-throughput preparation; slightly better reproducibility than the pipette method.

Limitations: Stirring and injection rates are difficult to control precisely, potentially resulting in a broader size distribution.

3.3.3 Microfluidic Mixing Method

• Prepare the microfluidic mixing equipment, setting a total flow rate of 8-12 mL/min and a flow rate ratio (aqueous:organic) of 3:1.
• Load the RNA solution (aqueous phase) and the lipid mixture solution (organic phase) into separate syringes and connect them to the corresponding inlets of the microfluidic chip.
• Start the mixing program and collect the LNP suspension flowing from the chip's outlet.
• Incubate the resulting mixture at room temperature for 10-15 minutes.
• Proceed with downstream purification as per Section 3.4.

Note 5: Microfluidic mixing enables precisely controlled rapid mixing, significantly improving LNP size uniformity and encapsulation efficiency, with optimal batch-to-batch reproducibility. LNP properties (like size and distribution) can be further optimized by adjusting parameters such as the total flow rate and flow rate ratio.

3.4 Purification and Post-Processing

Regardless of the mixing method used, the crude LNPs must undergo the following purification steps:

Buffer Exchange and Ethanol Removal:

• Dialysis Method: Transfer the crude LNPs to a dialysis bag (MWCO 10-14 kDa) and dialyze against 1× PBS buffer (pH 7.4) at 4°C for 2 hours. For more thorough ethanol removal, replace with fresh PBS and continue dialyzing overnight.
• Ultrafiltration Method: Add crude LNPs to an ultrafiltration tube (MWCO 100 kDa) and centrifuge at 3000-4000 ×g at 4°C to concentrate. Add PBS (pH 7.4) to resuspend, and repeat 2-3 times to fully exchange the buffer and remove ethanol.

Sterile Filtration: Filter the purified LNPs using a 0.22 μm sterile membrane for sterilization. It is recommended to sample and measure particle size before and after filtration to confirm the operation did not cause LNP aggregation or loss.

Storage: Aliquot and store the filtered LNPs. For short-term use (1-2 weeks), store at 4°C; for long-term storage, -80°C is recommended to avoid repeated freeze-thaw cycles.

3.5 Summary of Process Parameters

3.6 Precautions

• Lipid weighing and transfer: Ionizable lipids like MC3 are highly viscous; weighing should be used to ensure accurate quantification. All lipid handling should be performed in a fume hood.
• PEG lipid stability: PEG2000-C-DMG easily hydrolyzes in solution; it is advised to prepare the mixed lipid working solution fresh and avoid long-term storage.
• Precise pH control: The sodium acetate buffer pH must be accurately adjusted to 4.0-5.0. A high pH (>5.5) will reduce MC3 protonation, leading to a significant drop in RNA encapsulation.
• Temperature control: Cholesterol ethanol solutions crystallize easily at low temperatures and must be preheated to dissolve prior to use. Prevent the organic phase from becoming too cold during preparation to avoid lipid precipitation.
• Mixing rate: For manual mixing, injection speed and mixing intensity are crucial for determining size distribution. Using microfluidic equipment is recommended for optimal reproducibility.

V. General Precautions

• Lipid weighing and storage: MC3 has a distinct odor and must be handled in a fume hood and sealed promptly. PEG lipids (especially DMG-PEG2000) readily hydrolyze in solution; prepare organic phases fresh and avoid storage.
• Buffer pH control: The sodium acetate buffer pH must be precise (pH 4.0-5.0). A pH >5.5 reduces MC3 protonation, heavily impacting encapsulation efficiency. Verify with a calibrated pH meter after preparation.
• Presence of empty LNPs: Studies show that even with standard encapsulation rates, a certain proportion of empty LNPs (containing no mRNA) may still exist in the system. This must be considered when interpreting in vivo dose-response effects.
• In vitro-in vivo activity discrepancies: MC3 system LNPs might exhibit lower in vitro characterization performance (e.g., HEK293 cell transfection) than newer generations of ionizable lipids, but they still maintain excellent delivery efficiency in vivo; this is a known characteristic of the system.